Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1318-1327

  Birrell, Mark A ^a   Wong, Sissie ^a   McCluskie, Kerryn ^a   Catley, Matthew C ^a   Hardaker, Elizabeth L ^a   Haj Yahia, Saleem ^b   Belvisi, Maria G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; CELL PROTEIN; CYTOKINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYELOPEROXIDASE; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EOSINOPHIL COUNT; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG ALVEOLUS MACROPHAGE; MALE; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; RESPIRATORY TRACT INFLAMMATION; SOMATIC CELL GENETICS; TRANSCRIPTION REGULATION; TRANSLATION INITIATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DEXAMETHASONE; HUMANS; IMIDAZOLES; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGES; MALE; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; TRANSCRIPTION, GENETIC;

EID: 33644787093     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093310     Document Type: Article

References (26)

1. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, and Belvisi MG (2005) Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κB- independent mechanism. FASEB J 19:840-841.
2. Brook M, Sully G, Clark AR, and Saklatvala J (2000) Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett 483:57-61.
3. Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM, and Foxwell BM (2004) A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol 173:6928-6937.
4. Carter AB, Monick MM, and Hunninghake GW (1999) Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 20:751-758.
5. Chen KD, Chen LY, Huang HL, Lieu CH, Chang YN, Chang MD, and Lai YK (1998) Involvement of p38 mitogen-activated protein kinase signaling pathway in the rapid induction of the 78-kDa glucose-regulated protein in 9L rat brain tumor cells. J Biol Chem 273:749-755.
6. Dean JL, Brook M, Clark AR, and Saklatvala J (1999) p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 274:264-269.
7. Haddad EB, Birrell M, McCluskie K, Ling A, Webber SE, Foster ML, and Belvisi MG (2001) Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 132:1715-1724.
8. Koch A, Giembycz M, Ito K, Lim S, Jazrawi E, Barnes PJ, Adcock I, Erdmann E, and Chung KF (2003) Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. Am J Respir Cell Mol Biol 30:342-349.
9. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, and Gaestel M (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1:94-97.
10. Lali FV, Hunt AE, Turner SJ, and Foxwell BM (2000) The pyridinyl imidazole inhibitor SB6 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275:7395-7402.
11. Lee JC, Kassis S, Kumar S, Badger A, and Adams JL (1999) p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 82:389-397.
12. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Landvatter SW, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (Lond) 372:739-746.
13. Manthey CL, Wang SW, Kinney SD, and Yao Z (1998) SB 202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol 64:409-417.
14. Newton R and Holden N (2003) Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? BioDrugs 17:113-129.
15. Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, and Worthen GS (1999) Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Investig 103:851-858.
16. Nick JA, Young SK, Arndt PG, Lieber JG, Suratt BT, Poch KR, Avdi NJ, Malcolm KC, Taube C, Henson PM, et al. (2002) Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol 169:5260-5269.
17. Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, Suratt BT, Janes MS, Henson PM, and Worthen GS (2000) Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol 164:2151-2159.
18. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, and Sonenberg N (1999) Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO (Eur Mol Biol Organ) J 18:270-279.
19. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, and Davis RJ (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16:1247-1255.
20. Saccani S, Pantano S, and Natoli G (2002) p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3:69-75.
21. Schafer PH, Wang L, Wadsworth SA, Davis JE, and Siekierka JJ (1999) T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. J Immunol 162:659-668.
22. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, and Griswold DE (2000a) SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9 and fibrosis in lung. Am J Physiol 279:L895-L902.
23. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, et al. (2000b) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration and persistence. J Pharmacol Exp Ther 293:281-288.
24. Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein HS, and Manthey CL (1999) Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res 48:533-538.
25. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, and Cooper JA (1999) Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 19:1871-1880.
26. Young P, McDonnell P, Dunnington D, Hand A, Laydon J, and Lee J (1993) Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 39:C67-C69.